NCCN Guidelines Insights: Breast Cancer, Version 3.2018
- PMID: 30787125
- DOI: 10.6004/jnccn.2019.0009
NCCN Guidelines Insights: Breast Cancer, Version 3.2018
Abstract
These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.
Copyright © 2019 by the National Comprehensive Cancer Network.
Publication types
MeSH terms
LinkOut - more resources
- Full Text Sources
- Medical
- Research Materials
- Miscellaneous
 
        